A Phase I Trial of BBR 2778 in Combination With Fludarabine, Dexamethasone and Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Trial Profile

A Phase I Trial of BBR 2778 in Combination With Fludarabine, Dexamethasone and Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2015

At a glance

  • Drugs Pixantrone (Primary) ; Dexamethasone; Fludarabine; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 17 Jun 2011 Final results published early online in "Cancer".
    • 21 Sep 2008 Actual end date identified as May 2007, as reported by ClinicalTrials.gov.
    • 26 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top